Masayoshi Yamaguchi, Ph.D., IOM, FAOE, DDG, DG, is Adjunct Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA (2013 -). Dr. Yamaguchi is engaged in the fields of endocrinology and cell signaling since 1971, and these researches are developed in the aspect of biochemistry, molecular biology, endocrinology, metabolism, nutrition, pharmacology, and toxicology. Dr. Yamaguchi has an interesting for cell signaling mechanism, bone biology, nutritional factor and osteoporosis prevention, diabetes and diabetic osteoporosis, cancer biology, and cancer cell bone metastasis. Dr. Yamaguchi discovered two novel proteins and genes; cell signaling suppressor protein (named regucalcin; 1978)
Masayoshi Yamaguchi, Ph.D., IOM, FAOE, DDG, DG, is Adjunct Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA (2013 -). Dr. Yamaguchi is engaged in the fields of endocrinology and cell signaling since 1971, and these researches are developed in the aspect of biochemistry, molecular biology, endocrinology, metabolism, nutrition, pharmacology, and toxicology. Dr. Yamaguchi has an interesting for cell signaling mechanism, bone biology, nutritional factor and osteoporosis prevention, diabetes and diabetic osteoporosis, cancer biology, and cancer cell bone metastasis. Dr. Yamaguchi discovered two novel proteins and genes; cell signaling suppressor protein (named regucalcin; 1978) and transcriptional factor RGPR-p117 (regucalcin gene promoter region-related protein; 2001). Dr. Yamaguchi generated regucalcin transgenic rats, which were registered as international patents including USA, EU and Japan, and this animal was found to induce osteoporosis and hyperlipidemia. Moreover, Dr. Yamaguchi proposed the potential role of regucalcin as a key suppressor protein in carcinogenesis. Thus far, Dr. Yamaguchi published over 550 English articles to professional journals with peer-review, and registered over 20 national and international patents.
Dr. Baiyan Li, MD & PhD, is a Professor of Pharmacology in the Department of Pharmacology, School of Pharmacy, Harbin Medical University and Principle Investigator of Key Laboratory of Cardiovascular Research of Ministry of Education in Harbin Medical University, Harbin, China. Dr. Li is also Principle Investigator in the Laboratory of Neuroscience and Electrophysiology in Harbin Medical University. Dr. Li has currently collaborations with Dr. Hiroki Yokota at Department of Biomedical Engineering of Purdue University, Dr. Yue Wang at Department of Molecular Genetics, Dr. Michael Rubart and Dr. Weinian Shou at Riley Heart Research Center, Indiana University School of Medicine,
Dr. Baiyan Li, MD & PhD, is a Professor of Pharmacology in the Department of Pharmacology, School of Pharmacy, Harbin Medical University and Principle Investigator of Key Laboratory of Cardiovascular Research of Ministry of Education in Harbin Medical University, Harbin, China. Dr. Li is also Principle Investigator in the Laboratory of Neuroscience and Electrophysiology in Harbin Medical University. Dr. Li has currently collaborations with Dr. Hiroki Yokota at Department of Biomedical Engineering of Purdue University, Dr. Yue Wang at Department of Molecular Genetics, Dr. Michael Rubart and Dr. Weinian Shou at Riley Heart Research Center, Indiana University School of Medicine, USA. Dr. Li has made significant original contributions to the baroreflex afferent function and neurocontrol of circulation, especially the sexual dimorphism in hypertension in rats, ion channel mechanism of arrhythmia in genetic mouse model. He established nodose ganglia slice with intact Vagus using adult rats and has identified myelinated Ah-type baroreceptor afferents upon the afferent conduction.
Akira Sugawara Professor, Department of Molecular Endocrinology,Tohoku University Graduate School of Medicine, Japan. He is Research Fellow in Genetics, Howard Hughes Medical Institute/Harvard Medical School, Boston, 1992-1994. He is Chief, Department of Endocrinology and Diabetes, Miyagi Cancer Center. He is Chief, Department of Endocrinology and Diabetes, Miyagi Cancer Center in 2011-2012. He is an Editorila Board member for Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Endocrine Journal, Advances in Biological Chemistry. Research Interest are Molecular Biology of Nuclear Hormone Receptors, Etiology of High Blood Pressure, Pathophysiology of Diabetic Nephropathy, Gene Regulation of Aldosterone Synthesis, Epigenetics of Hypertension
Akira Sugawara Professor, Department of Molecular Endocrinology,Tohoku University Graduate School of Medicine, Japan. He is Research Fellow in Genetics, Howard Hughes Medical Institute/Harvard Medical School, Boston, 1992-1994. He is Chief, Department of Endocrinology and Diabetes, Miyagi Cancer Center. He is Chief, Department of Endocrinology and Diabetes, Miyagi Cancer Center in 2011-2012. He is an Editorila Board member for Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Endocrine Journal, Advances in Biological Chemistry. Research Interest are Molecular Biology of Nuclear Hormone Receptors, Etiology of High Blood Pressure, Pathophysiology of Diabetic Nephropathy, Gene Regulation of Aldosterone Synthesis, Epigenetics of Hypertension and Diabetes Mellitus.
My research focuses on epithelial cell biology and physiology with emphasis on understanding mechanisms and regulation of ion transport and on innate immune function of the airway epithelium in cystic fibrosis, asthma and allergic airway disease. Cultured human airway epithelial cells are currently used to study regulation of ion transport and cell migration by a variety of signaling molecules. A combination of electrophysiological approaches and molecular techniques provide a means of identifying transport mechanisms and signaling pathways that are important in controlling salt and fluid movement across the airway epithelium. Studies of innate immune function address the role of the
My research focuses on epithelial cell biology and physiology with emphasis on understanding mechanisms and regulation of ion transport and on innate immune function of the airway epithelium in cystic fibrosis, asthma and allergic airway disease. Cultured human airway epithelial cells are currently used to study regulation of ion transport and cell migration by a variety of signaling molecules. A combination of electrophysiological approaches and molecular techniques provide a means of identifying transport mechanisms and signaling pathways that are important in controlling salt and fluid movement across the airway epithelium. Studies of innate immune function address the role of the airway epithelium in allergic inflammation induced by environmental allergens and fungal infection of the lung. More recently, my laboratory has been investigating the role of oxidative stress and purinergic signaling in the secretion of IL-33 from airway epithelial cells and its contribution to allergic airway inflammation.
Dr. Re got his MD Degree in the Medical Faculty of the Ancona University in 1983. During his career at the Pharmacological Department of the same University he cooperated with Max Plank Institute of Gottingen (Germany) and Fidia Georgetown University (USA) for the characterization of neuromediators release in central and peripheral synapses. During these years he published many articles regarding Patch Clamp technique and on the Phase IV Drug Surveillance Program in cooperation with WHO. Until 2010 was Professor of Clinical Pharmacology and Toxicology in the same University. Since 1991 started his interest in the field of Natural Medicine and
Dr. Re got his MD Degree in the Medical Faculty of the Ancona University in 1983. During his career at the Pharmacological Department of the same University he cooperated with Max Plank Institute of Gottingen (Germany) and Fidia Georgetown University (USA) for the characterization of neuromediators release in central and peripheral synapses. During these years he published many articles regarding Patch Clamp technique and on the Phase IV Drug Surveillance Program in cooperation with WHO. Until 2010 was Professor of Clinical Pharmacology and Toxicology in the same University. Since 1991 started his interest in the field of Natural Medicine and Ozone Therapy. Invited by the DOHMS of Dubai UAE in 2002 contributed to the development of the Ozone Center in Rashid Hospital. Member of the Advisory Board of FIO (Italian Federation of Ozone Therapy). Awarded with Riccardo Monti Prize for Scientific work done to spread ozone practice in Italy and around the world, Florence, May 2013.
Hiroshi Yoshida, M.D., Ph,D., FACP is Professor of Department of Laboratory Medicine, Jikei University School of Medicine, and jointly appointed as Professor of Internal Medicine of Metabolism and Nutrition, Jikei University Graduate School of Medicine. He is also Vice-President of Jikei University Kashiwa Hospital. He obtained Ph.D degree in National Defense Medical College. He studied as Research Fellow in University of California San Diego, U.S.A. (1996-1998). He Received the Encouragement Prize from Japanese Society of Laboratory Medicine in 2004, and Life Science Award from Japanese Society of Laboratory Medicine in 2009. He was collectively awarded Evergreen Award to Publication
Hiroshi Yoshida, M.D., Ph,D., FACP is Professor of Department of Laboratory Medicine, Jikei University School of Medicine, and jointly appointed as Professor of Internal Medicine of Metabolism and Nutrition, Jikei University Graduate School of Medicine. He is also Vice-President of Jikei University Kashiwa Hospital. He obtained Ph.D degree in National Defense Medical College. He studied as Research Fellow in University of California San Diego, U.S.A. (1996-1998). He Received the Encouragement Prize from Japanese Society of Laboratory Medicine in 2004, and Life Science Award from Japanese Society of Laboratory Medicine in 2009. He was collectively awarded Evergreen Award to Publication Committee of Japan Chapter from American College of Physician in 2008. He is currently an editorial board member of Japanese Journal of Clinical Chemistry, World Journal of Cardiology, ISRN Vascular Medicine, Journal of Cardiology and Therapy, Journal of Functional Foods in Health and Disease, Journal of Geriatric Cardiology, JSM Biomarkers, Journal of Nutritional Science and Vitaminology. He has more than 100 published papers indexed in PubMed. Research Interest are Atherosclerosis, Cardiovascular Medicine, Clinical Nutrition, Clinical Pharmacology, Lipid Metabolism, Oxidative Stress.
Sho-ichi Yamagishi, MD, PhD is Professor and Chairman of Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Japan. He has received a PhD from Kanazawa University, Japan in 1993. He received Angiogenesis Stem Cell Award from AHA in 2003, Distinguished Investigator Award from Japan Diabetes Society in 2005, and Research Award from Japanese Society of Anti-Aging Medicine in 2012. He is serving as an editorial board member of reputed journals and published more than 500 research papers, including Nature, JCI, JACC, JASN, Diabetes, Diabetes Care, and FASEB J. His research interest is Diabetes, Cardiology,
Sho-ichi Yamagishi, MD, PhD is Professor and Chairman of Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Japan. He has received a PhD from Kanazawa University, Japan in 1993. He received Angiogenesis Stem Cell Award from AHA in 2003, Distinguished Investigator Award from Japan Diabetes Society in 2005, and Research Award from Japanese Society of Anti-Aging Medicine in 2012. He is serving as an editorial board member of reputed journals and published more than 500 research papers, including Nature, JCI, JACC, JASN, Diabetes, Diabetes Care, and FASEB J. His research interest is Diabetes, Cardiology, Glycation and Oxidative Stress.
Prof. Kyuzi Kamoi was born August 28, 1943 in Tokyo, Japan. He received his MD in 1970 and his MSD in 1982, both from the Medical School of Niigata University, Niigata, Japan. He has received the following certificates: Japan Medical Diplomat (1970), Japan Board of Diabetes Mellitus (1990), Japan Board of Endocrinology and Metabolism (1991), Certified Diabetes Mellitus Educator (1993), Certified Endocrine Educator (2004). From 1980 to 2010 he was Chief of Internal Medicine, and from 2002 until 2010 the Director of Center of Diabetes Mellitus and Endocrine Disease at Nagaoka Red Cross Hospital, Japan. Since 2010 to the present
Prof. Kyuzi Kamoi was born August 28, 1943 in Tokyo, Japan. He received his MD in 1970 and his MSD in 1982, both from the Medical School of Niigata University, Niigata, Japan. He has received the following certificates: Japan Medical Diplomat (1970), Japan Board of Diabetes Mellitus (1990), Japan Board of Endocrinology and Metabolism (1991), Certified Diabetes Mellitus Educator (1993), Certified Endocrine Educator (2004). From 1980 to 2010 he was Chief of Internal Medicine, and from 2002 until 2010 the Director of Center of Diabetes Mellitus and Endocrine Disease at Nagaoka Red Cross Hospital, Japan. Since 2010 to the present he has been Professor of Niigata Prefecture University. He is a member of The Japanese Society of Internal Medicine, The Japan Endocrine Society, The Japanese Society of Hypertension, The Japan Society of Hypertension, the Endocrine Society, The American Society of Hypertension, The American Diabetes Association, The International Diabetes Federation and the New York Academy of Science. He has published a total of 200 scientific papers. Research interests are Endocrinology and Metabolism, Health Sciences, Medicine.
Dr. Dayue Darrel Duan, MD, PhD, FAHA, is a Professor of Pharmacology in the Department of Pharmacology and Principle Investigator of the Laboratory of Cardiovascular Phenomics in the Center for Molecular Medicine at School of Medicine, University of Nevada in Reno, Nevada, USA. Dr. Duan discovered several anion channels in the heart and has made significant original contributions to the study of biophysics, physiology, pharmacology, and molecular biology of ion channels in the cardiovascular system. His current research is focusing on the phenomics, functional genomics and proteomics of ion channels in the cardiovascular systems. The Duan laboratory has established several
Dr. Dayue Darrel Duan, MD, PhD, FAHA, is a Professor of Pharmacology in the Department of Pharmacology and Principle Investigator of the Laboratory of Cardiovascular Phenomics in the Center for Molecular Medicine at School of Medicine, University of Nevada in Reno, Nevada, USA. Dr. Duan discovered several anion channels in the heart and has made significant original contributions to the study of biophysics, physiology, pharmacology, and molecular biology of ion channels in the cardiovascular system. His current research is focusing on the phenomics, functional genomics and proteomics of ion channels in the cardiovascular systems. The Duan laboratory has established several animal models for cardiac diseases and hypertension and has the capacity to study the genome-phenome relationship and molecular mechanisms for cardiovascular disease at multiple levels ranging from whole animal to molecular levels. He delivered over 150 invited lectures and seminars throughout the world, and has published more than 80 peer-reviewed papers and book chapters.
Professor Petroianu serves as Chairman of the Department of Cellular Biology and Associate Dean for Clinical Research in the FIU College of Medicine. He has been on exam committees and written several Q&A books for residents preparing for certification exams. Dr. Petroianu has received multiple teaching awards, such as numerous Best Lecturer Awards at University of Heidelberg at Mannheim and the Excellence in Teaching Award at the United Arab Emirates University. Dr. Petroianu received his PhD, MD and Habilitation from the University of Heidelberg at Mannheim. He has worked in Anesthesiology and Emergency Medicine and has board certifications in Pharmacology
Professor Petroianu serves as Chairman of the Department of Cellular Biology and Associate Dean for Clinical Research in the FIU College of Medicine. He has been on exam committees and written several Q&A books for residents preparing for certification exams. Dr. Petroianu has received multiple teaching awards, such as numerous Best Lecturer Awards at University of Heidelberg at Mannheim and the Excellence in Teaching Award at the United Arab Emirates University. Dr. Petroianu received his PhD, MD and Habilitation from the University of Heidelberg at Mannheim. He has worked in Anesthesiology and Emergency Medicine and has board certifications in Pharmacology and Toxicology (Germany) and Clinical Pharmacology (American Board of Clinical Pharmacology). He also is a Diplomat of the American Academy of Pain Management. He remained on the Faculty at University of Heidelberg at Mannheim and rose through the ranks until 2002, when he became Chair of the Department of Pharmacology and Therapeutics at the United Arab Emirates University. He is now leading a large department with multiple research and educational responsibilities and remains active at the College level, serving on numerous committees. Dr. Petroianu has authored more than 150 peer-reviewed research papers, 60 other non-abstracted publications and several books. His most recent research is on cholinesterase protection and reactivation in relation to organophosphate exposure. For his contribution to Pharmacology, Dr. Petroianu was awarded the Issekutz Medal of the Hungarian Society of Pharmacology and Toxicology and received an Honorary Doctoral Degree from the Semmelweis University in Budapest.
Dr. Yi Charlie Chen, professor of biology, has taught at Alderson Broaddus University since 2000. He received his B.S. and M.S. from Zhejiang University in China. He then received his second M.S. and Ph.D. from Washington State University. Dr. Chen has published over 54 different papers and book chapters in a wide range of scientific journals and books. Dr. Chen is currently working on molecular biology of cancer research. His research has focused on the inhibition of anti-cancer drugs, especially natural compounds, on cancer growth with emphasis on angiogenesis and apoptosis. Dr. Chen is also working on nanochemoprevention using
Dr. Yi Charlie Chen, professor of biology, has taught at Alderson Broaddus University since 2000. He received his B.S. and M.S. from Zhejiang University in China. He then received his second M.S. and Ph.D. from Washington State University. Dr. Chen has published over 54 different papers and book chapters in a wide range of scientific journals and books. Dr. Chen is currently working on molecular biology of cancer research. His research has focused on the inhibition of anti-cancer drugs, especially natural compounds, on cancer growth with emphasis on angiogenesis and apoptosis. Dr. Chen is also working on nanochemoprevention using nanoparticles as a novel approach for cancer control. Dr. Chen is the recipient of the Faculty of the Year Award in 2013. He was also the featured professor in the 2013 spring issue of the Neuron: West Virginia Journal of Science and Research.
I am now working on signal transduction. I discovered DAB: the regulators of Ca2+ release and conseqent cellular processes. My typical paper is Ozaki Shoichiro. Chemical approach to signal transduction by inositol trisphoaphate. I succeeded in the first total synthesis of of optically active myo-inositol tris(1,4,5) phosphate. Research Interest are inositol trisphosphate, regulator of cellular process, DAB, IP3.
I am now working on signal transduction. I discovered DAB: the regulators of Ca2+ release and conseqent cellular processes. My typical paper is Ozaki Shoichiro. Chemical approach to signal transduction by inositol trisphoaphate. I succeeded in the first total synthesis of of optically active myo-inositol tris(1,4,5) phosphate. Research Interest are inositol trisphosphate, regulator of cellular process, DAB, IP3.
Sridhar Mani is the Founding Director of the Phase I Experimental Therapeutics Program at the Montefiore/Einstein Cancer Center. He received his MD degree (1990) from the Mount Sinai School of Medicine, New York, NY followed by further postdoctoral training in Internal Medicine and Hematology/Oncology at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT. He was a permanent member of the Developmental Therapeutics Study Section of NCI (2013) and serves as an editorial board member for Clinical Cancer Research, Journal of Biological Chemistry, Molecular Pharmacology and Molecular Cancer Therapeutics (AACR). He has more than 100 peer-reviewed papers
Sridhar Mani is the Founding Director of the Phase I Experimental Therapeutics Program at the Montefiore/Einstein Cancer Center. He received his MD degree (1990) from the Mount Sinai School of Medicine, New York, NY followed by further postdoctoral training in Internal Medicine and Hematology/Oncology at Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT. He was a permanent member of the Developmental Therapeutics Study Section of NCI (2013) and serves as an editorial board member for Clinical Cancer Research, Journal of Biological Chemistry, Molecular Pharmacology and Molecular Cancer Therapeutics (AACR). He has more than 100 peer-reviewed papers in journals like Science, Cancer Research, Clinical Cancer Research, Molecular Pharmacology, Molecular Endocrinology, Molecular Cancer Therapeutics, Immunity and Journal of Clinical Oncology. His research interests are Orphan nuclear receptors control nearly every major physiologic and biochemical process in eukaryotes-cell metabolism, xenobiotic detoxification, cell differentiation, circadian rhythm, and cancer cell growth and apoptosis. Broad interest in clinical pharmacology for xenobiotics and drugs across health disciplines.
I am an Associate Professor in University of the Ryukyus and live in Okinawa, Japan. I am interested in research as follows Near-infrared (NIR) spectroscopy for clinical chemistry and laboratory medicine, Diseases in Okinawa and subtropical region, Function of prion protein, Development of sterilization technology. I received awards as follows An award from the Japanese Society for Host Defense Research in 2006. An award from the Japanese Society of Veterinary Science in 2009 and 2013. 2006 Award for best poster from the Forum of Near-Infrared Spectroscopy in Japan. 2011 NIR Advance Award from the Japan Council for Near Infrared Spectroscopy.
I am an Associate Professor in University of the Ryukyus and live in Okinawa, Japan. I am interested in research as follows Near-infrared (NIR) spectroscopy for clinical chemistry and laboratory medicine, Diseases in Okinawa and subtropical region, Function of prion protein, Development of sterilization technology. I received awards as follows An award from the Japanese Society for Host Defense Research in 2006. An award from the Japanese Society of Veterinary Science in 2009 and 2013. 2006 Award for best poster from the Forum of Near-Infrared Spectroscopy in Japan. 2011 NIR Advance Award from the Japan Council for Near Infrared Spectroscopy. 1st Nanointerface Innovative Award from the Committee of Frontier Science of Interactions between Plasmas and Nanointerfaces in 2011.
Dr. Mukesh Kumar is an Instructor in the Department of Tropical Medicine, Medical Microbiology and Pharmacology (DTMMMP), and Associate Director of the John A. Burns School of Medicine (JABSOM) Biocontainment Facility (JBF) at University of Hawaii at Manoa (UHM). Dr. Kumar is a trained veterinarian with a Ph.D. in Tropical Medicine. He conducts independent research as well as assists other independent principal investigators, graduate students and technicians in conducting their research projects in the JBF. Dr. Kumars major area of research interest is in infectious diseases, specifically viral immunopathogenesis and virus-host interactions. He conducts research on various emerging pathogens including
Dr. Mukesh Kumar is an Instructor in the Department of Tropical Medicine, Medical Microbiology and Pharmacology (DTMMMP), and Associate Director of the John A. Burns School of Medicine (JABSOM) Biocontainment Facility (JBF) at University of Hawaii at Manoa (UHM). Dr. Kumar is a trained veterinarian with a Ph.D. in Tropical Medicine. He conducts independent research as well as assists other independent principal investigators, graduate students and technicians in conducting their research projects in the JBF. Dr. Kumars major area of research interest is in infectious diseases, specifically viral immunopathogenesis and virus-host interactions. He conducts research on various emerging pathogens including West Nile virus, Japanese Encephalitis virus and hanta viruses using cell culture models, mouse models and biological specimens. His work encompasses both basic research in trying to understand more thoroughly how these agents cause disease and how the human immune system responds to these infections, and more directed research in developing and evaluating vaccines and other tools to prevent infection by these agents. His work also involves developing novel small animal models to study infectious pathogens. Dr. Kumar has published several outstanding papers in top international journals and his research findings are widely cited.
Rafat Siddiqui, PhD is the Senior Investigator and Director of the Cellular Biochemistry Research Laboratory at Indiana University Health Methodist Research Institute. Dr. Siddiqui is also an adjunct professor in the Department of Medicine, Indiana University Medical School, Indianapolis and is an internationally recognized expert in many areas of Lipid Biology pertinent to cancer, cardiovascular disease, inflammation and the neurosciences. He has published over 100 scientific papers in peer-reviewed journals and has been the invited keynote speaker at several national and international conferences. He also serves on the editorial board of the British Journal of Nutrition, Journal of Nutrition Sciences,
Rafat Siddiqui, PhD is the Senior Investigator and Director of the Cellular Biochemistry Research Laboratory at Indiana University Health Methodist Research Institute. Dr. Siddiqui is also an adjunct professor in the Department of Medicine, Indiana University Medical School, Indianapolis and is an internationally recognized expert in many areas of Lipid Biology pertinent to cancer, cardiovascular disease, inflammation and the neurosciences. He has published over 100 scientific papers in peer-reviewed journals and has been the invited keynote speaker at several national and international conferences. He also serves on the editorial board of the British Journal of Nutrition, Journal of Nutrition Sciences, International Journal of Chemistry and Pharmaceutical Research, American Journal of Biochemistry and Molecular Biology, International Journal of Biological Chemistry, Journal of Biological Science, Asian Journal of Biochemistry, Advances in Biological Chemistry, Enliven: Challenges in Cancer, Cancer Research Journal, Journal of Molecular and Genetic Medicine, Journal of International Dental and Medical Research, Journal of Glycomics and Lipidomics, and Research Journal of Developmental Biology. His recent work focuses on the synergistic modulation of cancer progression by a combination of nutrients and drugs with omega-3 fatty acids, and he holds a patent on fatty acid-phenolic conjugates for anticancer effects. Dr. Siddiqui earned his BSc and MSc degrees in Biochemistry from the University of Karachi, in Karachi, Pakistan. He obtained his PhD from the Australian National University in Canberra, Australia. Dr. Siddiqui served as a postdoctoral fellow at Massey University in Palmerton North, New Zealand and immigrated to America in 1989 to work as a Howard Hughes fellow at Vanderbilt University Medical Center in Nashville, TN. Dr. Siddiquis research has been featured on BBC, FOXTV, and WTHR broadcasts, as well as in the Sun, Telegraph, and Indianapolis Star newspapers and several other media outlets.
Dr. Singh primary research interest includes in the area of cellular and mucosal immunology, inflammation in general, chemokines, immunotherapy and complimentary and alternative medicine. Dr. Singh is internationally recognized mucosal immunologist working in the area of inflammation since last 15 years. Dr. Singh research contributions span multiple disciplines including cellular and mucosal immunology related to alternative medicine in the pathogenesis of inflammatory bowel disease (IBD) and interstitial cystitis. Dr. Singh obtained his Ph.D. degree from Banaras Hindu University, in India. At present Dr. Singh focusing on how a plant derived compound and/or dietary supplement mediate murine colitis and interstitial cystitis.
Dr. Singh primary research interest includes in the area of cellular and mucosal immunology, inflammation in general, chemokines, immunotherapy and complimentary and alternative medicine. Dr. Singh is internationally recognized mucosal immunologist working in the area of inflammation since last 15 years. Dr. Singh research contributions span multiple disciplines including cellular and mucosal immunology related to alternative medicine in the pathogenesis of inflammatory bowel disease (IBD) and interstitial cystitis. Dr. Singh obtained his Ph.D. degree from Banaras Hindu University, in India. At present Dr. Singh focusing on how a plant derived compound and/or dietary supplement mediate murine colitis and interstitial cystitis. Dr. Singh have authored > 75 scientific communications including 1 patent applications, ~20 invited lectures. Dr. Singh long time career goal is to understand how alternative medicine remedies mediate IBD and Inflammation in general. Key words: Inflammation, Chemokines, mucosal Immunology, Interstitial cystitis, autoimmune diseases, Cellular Immunology, and Intestinal Physiology.
Dr Manuel Vazquez-Carrera obtained his Pharmacy degree at the University of Barcelona in 1990 with A mark. In 1991 he got a grant FPI of the Generalitat de Catalunya (for the period 1991-1994) for young researchers. Since then he has been working, as a research student at the Department of Pharmacology of the Faculty of Pharmacy of Barcelona. He finished his Ph.D. in December 1994. In 1995 Dr Vazquez-Carrera obtained a grant of the European Science Foundation for 1 year to perform a postdoctoral stage in the PPAR field at the Institut de Biologie Animale, Universite de Lausanne, Switzerland under
Dr Manuel Vazquez-Carrera obtained his Pharmacy degree at the University of Barcelona in 1990 with A mark. In 1991 he got a grant FPI of the Generalitat de Catalunya (for the period 1991-1994) for young researchers. Since then he has been working, as a research student at the Department of Pharmacology of the Faculty of Pharmacy of Barcelona. He finished his Ph.D. in December 1994. In 1995 Dr Vazquez-Carrera obtained a grant of the European Science Foundation for 1 year to perform a postdoctoral stage in the PPAR field at the Institut de Biologie Animale, Universite de Lausanne, Switzerland under the supervision of Dr. Walter Wahli. Currently, Dr. Vazquez-Carrera is a Lecturer in Pharmacology at the Faculty of Pharmacy of the University of Barcelona. Research interests are Inflammation and insulin resistance, Experimental models of Metabolic Syndrome: the fructose-fed rat and senescence-related models in rodents. Molecular basis and drug activity, Molecular basis of insulin resistance in skeletal muscle and modulation by drugs, Molecular basis of cardiac hypertrophy: Role of PPARs and inflammation-related Transcription Factors.
Dr. Kharbanda is currently a staff scientist at Department of Veterans Affairs, Nebraska Western Iowa HCS Medicine Department and an Associate Professor in Internal Medicine, Division of Gastroenterology-Hepatology at the University Nebraska Medical Center. Dr. Kharbanda obtained her Ph.D from the Department of Zoology, University of Delhi, India and was appointed Assistant Professor of Internal Medicine at the University of Nebraska Medical Center and as a staff biologist at Omaha VA in 1999. Dr. Kharbanda has published extensively in the pathogenesis of alcoholic liver injury and prevention by betaine treatment. Her principal research interest is to determine how alcohol-induced alterations
Dr. Kharbanda is currently a staff scientist at Department of Veterans Affairs, Nebraska Western Iowa HCS Medicine Department and an Associate Professor in Internal Medicine, Division of Gastroenterology-Hepatology at the University Nebraska Medical Center. Dr. Kharbanda obtained her Ph.D from the Department of Zoology, University of Delhi, India and was appointed Assistant Professor of Internal Medicine at the University of Nebraska Medical Center and as a staff biologist at Omaha VA in 1999. Dr. Kharbanda has published extensively in the pathogenesis of alcoholic liver injury and prevention by betaine treatment. Her principal research interest is to determine how alcohol-induced alterations in methionine metabolic pathways results in the development of liver injury. In particular, she is interested in consequent methylation defects that lead to the development of alcoholic steatosis, apoptosis and the accumulation of altered proteins - hallmark features of alcoholic liver injury. She is also evaluating the efficacy of betaine and betaine analogs and esters in preventing and treating liver injury of various etiologies including alcohol and non-alcoholic steatohepatitis. She has over 80 peer-reviewed publications and has grant funding from VA Merit review funds and NIAAA. Areas of Research include Alcohol-induced alterations in methionine metabolic pathways and methylation defects that play a causal role in the pathogenesis of alcoholic liver injury, Efficacy of betaine and betaine analogs and esters in preventing and treating liver injury of various etiologies including alcohol and non-alcoholic steatohepatitis, Examination of interactions of various liver cell types in the initiation and progression of alcoholic liver injury, Alterations in intestinal permeability and gut microbiome leading to systemic endotoxemia and its role in alcoholic liver injury.
Dr. Yan Li, an Associate Professor, worked at School of Medicine, University of Louisville. Dr. Yan Lis research interests focus on understanding carcinogenesis and cancer therapy. The goal of his lab is to study the biology of cancer stem cell and tumor microenvironment to provide the potential therapeutic strategy for clinical cancer patients. He has led a research group to study the anti-cancerous active components from several natural products including, taraxacum, scutellaria, and turmeric in China. Since he worked at the University of Louisville, he carried out studies on carcinogenesis of Barrett’s adenocarcinoma, pancreatic cancer, brain cancer, colon cancer and
Dr. Yan Li, an Associate Professor, worked at School of Medicine, University of Louisville. Dr. Yan Lis research interests focus on understanding carcinogenesis and cancer therapy. The goal of his lab is to study the biology of cancer stem cell and tumor microenvironment to provide the potential therapeutic strategy for clinical cancer patients. He has led a research group to study the anti-cancerous active components from several natural products including, taraxacum, scutellaria, and turmeric in China. Since he worked at the University of Louisville, he carried out studies on carcinogenesis of Barrett’s adenocarcinoma, pancreatic cancer, brain cancer, colon cancer and hepatocellular carcinoma, and served as a key investigator and principle investigator on NIH-funded grants. He has successfully administered several research projects. This experience is reflected in his publications (over 60) in peer-reviewed journals and funded research projects.
Haizhen Andrew Zhong is an Associate Professor of Chemistry at the University of Nebraska in Omaha, NE. He started his career as a medicinal chemist by earning M.Sc. in Medicinal Chemistry from School of Pharmaceutical Sciences at Peking University, and followed by Ph.D. in Medicinal Chemistry from College of Pharmacy at the University of Georgia, Athens, GA. After several years of postdoctoral experience with Dr. Heather A. Carlson at College of Pharmacy of University of Michigan and with Dr. J. Phillip Bowen at University of North Carolina at Greensboro, Dr. Zhong started his tenure-track position at University of Nebraska
Haizhen Andrew Zhong is an Associate Professor of Chemistry at the University of Nebraska in Omaha, NE. He started his career as a medicinal chemist by earning M.Sc. in Medicinal Chemistry from School of Pharmaceutical Sciences at Peking University, and followed by Ph.D. in Medicinal Chemistry from College of Pharmacy at the University of Georgia, Athens, GA. After several years of postdoctoral experience with Dr. Heather A. Carlson at College of Pharmacy of University of Michigan and with Dr. J. Phillip Bowen at University of North Carolina at Greensboro, Dr. Zhong started his tenure-track position at University of Nebraska at Omaha in 2007, where he obtained his tenure and promotion in 2013. His research is focused on using computational tools to investigate macromolecule-ligand interactions, particularly in the areas of computer-assisted anticancer drug design and synthesis with PI3K, EGFR and p53 as target proteins. Dr. Zhongs research has been published in several prestigious journals, including Journal of American Chemical Society, Journal of Chemical Theory and Computation, Journal of Chemical Information and Modeling, and Plos One. Studies on protein-protein, protein-ligand, and DNA-ligand interactions using molecular dynamics, binding free energy estimation and computational alanine scanning methods, Conformational studies of important small molecules, Pharmacophore modeling of VEGFG, MMP, EGFR, MDM2/p53, and PI3K inhibitors.
Dr.To is an Associate Professor at the School of Pharmacy, The Chinese University of Hong Kong, Hong Kong. He obtained his B.Pharm and Ph.D from the same school. He is also a registered pharmacist in Hong Kong. After graduation, he went to the United States to obtain post-doctoral research training in cancer research. He had studied multidrug resistance transporters and cancer epigenetics at the National Cancer Institute (NCI/NIH). Currently, his research group is devoted to cancer cell biology and drug transporter research. The goal is to develop novel strategies for eradicating cancer cells and to devise more specific prognostic
Dr.To is an Associate Professor at the School of Pharmacy, The Chinese University of Hong Kong, Hong Kong. He obtained his B.Pharm and Ph.D from the same school. He is also a registered pharmacist in Hong Kong. After graduation, he went to the United States to obtain post-doctoral research training in cancer research. He had studied multidrug resistance transporters and cancer epigenetics at the National Cancer Institute (NCI/NIH). Currently, his research group is devoted to cancer cell biology and drug transporter research. The goal is to develop novel strategies for eradicating cancer cells and to devise more specific prognostic biomarkers for predicting response to chemotherapy. They demonstrated the novel use of molecular targeted tyrosine kinase inhibitors in eradicating cancer stem-like cells and circumventing transporters-mediated chemo-resistance. Besides, the group studied the microRNA-mediated regulation of drug transporters and its prognostic application in predicting response to chemotherapy. Recently, they have initiated studies to understand how drug transporters may affect the efficacy of antihyperlipidemic drugs. Research Interest are Epigenetic regulation of drug transporters, Understanding drug resistance to molecularly targeted anticancer drugs, Adjuvant use of active constituents from traditional Chinese medicine in circumventing resistance to conventional anticancer drugs, Design of novel Platinum-based anticancer agents.
My research at MD Anderson is focused on identifying novel therapeutic agents for the treatment of leukemia, in particular for CLL, by understanding the metabolism, mechanism of action, and interactions with other therapies. The goal is to implement new agents in the clinic for the treatment of CLL. Understanding the molecular pathways involved in the action of chemotherapeutic agents is important in designing new clinical protocols for use in the clinical setting. Multiple clinical trials have been initiated at MD Anderson based on encouraging preclinical data obtained by me and my colleagues. Many chemotherapeutic agents display efficacy in preclinical studies.
My research at MD Anderson is focused on identifying novel therapeutic agents for the treatment of leukemia, in particular for CLL, by understanding the metabolism, mechanism of action, and interactions with other therapies. The goal is to implement new agents in the clinic for the treatment of CLL. Understanding the molecular pathways involved in the action of chemotherapeutic agents is important in designing new clinical protocols for use in the clinical setting. Multiple clinical trials have been initiated at MD Anderson based on encouraging preclinical data obtained by me and my colleagues. Many chemotherapeutic agents display efficacy in preclinical studies. However, their activity varies to a greater extent in clinical settings. For CLL cells, bone marrow or lymphnode microenvironments have greater influence on the evolution of the leukemic phenotype. Therefore, my interest is to understand the therapeutic response in presence of microenvironment and its association with clinical stage and prognosis.
My career started by earning M.Sc. in Medicinal Chemistry followed by Ph.D. in Pharmacology, after graduating from the School of Pharmacy of the University of Patras, Greece. Its major turning point was in 2004, when I joined the lab of Dr. Walter Koch, a former postdoctoral fellow of Nobel laureate Professor Robert Lefkowitz`s lab at Duke University. During my 5-year postdoctoral tenure there, I had several successes, awards and honors, most prominent among which being a lead-author publication in Nature Medicine and a 4-year Scientist Development Grant award by the American Heart Association (AHA) I currently hold. In addition, I
My career started by earning M.Sc. in Medicinal Chemistry followed by Ph.D. in Pharmacology, after graduating from the School of Pharmacy of the University of Patras, Greece. Its major turning point was in 2004, when I joined the lab of Dr. Walter Koch, a former postdoctoral fellow of Nobel laureate Professor Robert Lefkowitz`s lab at Duke University. During my 5-year postdoctoral tenure there, I had several successes, awards and honors, most prominent among which being a lead-author publication in Nature Medicine and a 4-year Scientist Development Grant award by the American Heart Association (AHA) I currently hold. In addition, I have been a post-doctoral research fellow of the AHA for a total of three years in the past, and, in fact, my postdoctoral fellowship application with AHA in 2007 got an unusual 1-year extension based on its exceptionally high score. I have also been a finalist for the AHA-sponsored Melvin L. Marcus Young Investigator Award in Basic Cardiovascular Sciences, and for the Cardiovascular Research Award of the Council on Basic Cardiovascular Sciences of the European Society of Cardiology (ESC), I hold two (provisional) research patents, and I currently serve on the Editorial Boards of two peer-reviewed journals, as a regular peer-reviewer for several prestigious journals, including British Journal of Pharmacology, Circulation Research, and American Journal of Cardiology, and as a research grant reviewer for AHA. In addition, I am an elected Fellow of the American Heart Association (FAHA) and its Council on Basic Cardiovascular Sciences (BCVS). Finally, I have published in various prestigious scientific journals, in addition to Nature Medicine, such as: Circulation, JACC, PNAS, JBC, Molecular Pharmacology, etc., and my papers are highly cited. His research interests are Molecular pharmacology, physiology and biology of G protein-coupled.
Dr. Yingyu Ma is an Assistant Professor of Oncology at the Department of Pharmacology and Therapeutics at Roswell Park Cancer Institute in Buffalo, NY. She completed her medical training at Peking University Health Science Center in China, graduate training in Life Sciences at Northwestern University in Chicago and postdoctoral training in pharmacology at Roswell Park Cancer Institute. Her main research focus is on antitumor effects of 1,25D3, the active vitamin D metabolite, and the development of therapeutic strategies utilizing 1,25D3. She has been involved in translational research projects in patients with bladder cancer. Her research interests include the understanding of
Dr. Yingyu Ma is an Assistant Professor of Oncology at the Department of Pharmacology and Therapeutics at Roswell Park Cancer Institute in Buffalo, NY. She completed her medical training at Peking University Health Science Center in China, graduate training in Life Sciences at Northwestern University in Chicago and postdoctoral training in pharmacology at Roswell Park Cancer Institute. Her main research focus is on antitumor effects of 1,25D3, the active vitamin D metabolite, and the development of therapeutic strategies utilizing 1,25D3. She has been involved in translational research projects in patients with bladder cancer. Her research interests include the understanding of the mechanisms of 1,25D3 regulation of cancer progression and metastasis, and the development of effective diagnostic, prognostic, and therapeutic biomarkers in bladder cancer. She is also interested in the mechanisms of 1,25D3 non-genomic signaling and apoptosis, as well as combination treatment with 1,25D3 and chemotherapeutic agents in squamous cell carcinoma and bladder cancer.
Xuchen Zhang, MD, PhD, is an assistant professor of pathology at Department of Pathology of VA Connecticut Health System & Yale University School of Medicine, who is board-certified in anatomic/clinical pathology. He has clinical interests in liver/GI pathology, and neoplastic and non-neoplastic pulmonary pathology. He completed his medical degree at Chengde Medical College, his master’s at Beijing University of Chinese Medicine and his doctorate at Chinese Academy of Medical Sciences/Peking Union Medical College. Dr. Zhang conducted research as Post-doc and Associate Research Scientist at Yale University School of Medicine from 2000 to 2007 in the field of acute and chronic
Xuchen Zhang, MD, PhD, is an assistant professor of pathology at Department of Pathology of VA Connecticut Health System & Yale University School of Medicine, who is board-certified in anatomic/clinical pathology. He has clinical interests in liver/GI pathology, and neoplastic and non-neoplastic pulmonary pathology. He completed his medical degree at Chengde Medical College, his master’s at Beijing University of Chinese Medicine and his doctorate at Chinese Academy of Medical Sciences/Peking Union Medical College. Dr. Zhang conducted research as Post-doc and Associate Research Scientist at Yale University School of Medicine from 2000 to 2007 in the field of acute and chronic oxidant-induced lung injury. In addition, he completed his pathology residency at State University of New York at Downstate Medical Center, and Liver/GI pathology fellowship at Mount Sinai School of Medicine. He is serving as reviewer and editorial board member for several journals, and has more than 70 publications. His research interests are drug-induced hepatotoxicity and gastrointestinal injury, acute and chronic oxidant-induced lung injury and underlying molecular mechanisms.
Dr. Yeon Sun Lee is a Research Assistant Professor in the Department of Chemistry and Biochemistry at the University of Arizona in Tucson, AZ. She joined the University of Arizona in 2000, and since then has been conducting research in Drug Discovery to treat chronic neuropathic pain with a new pathological paradigm. Before joining the University of Arizona, she worked for Hyundai Pharmaceutical in Korea for 5 years. At that time, as a team leader of a Peptide Lab, she developed new amino acid derivatives and new synthetic methodologies for biologically active peptide ligands. Originally her major was synthetic organic
Dr. Yeon Sun Lee is a Research Assistant Professor in the Department of Chemistry and Biochemistry at the University of Arizona in Tucson, AZ. She joined the University of Arizona in 2000, and since then has been conducting research in Drug Discovery to treat chronic neuropathic pain with a new pathological paradigm. Before joining the University of Arizona, she worked for Hyundai Pharmaceutical in Korea for 5 years. At that time, as a team leader of a Peptide Lab, she developed new amino acid derivatives and new synthetic methodologies for biologically active peptide ligands. Originally her major was synthetic organic chemistry, in which she received her doctoral degree from Ewha Womans University in Korea in 1994. After receiving her Ph.D. degree, she worked for the Korea Institute of Science and Technology as a post-doc for 1 year. Now Dr. Lees main focus is to discover novel peptide ligands with increased drugability interacting with opioid receptors or non-opioid receptors such as bradykinin receptors, which has been identified as a new target for dynorphin, to treat abnormal pain states caused by chronic pain or nerve injury.
Dr. Daniel Ontaneda is an Assistant Professor of Medicine/Neurology at The Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Staff Neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic. He received his medical degree from The Pontificia Universidad CatoÃŒÂlica del Ecuador and holds a Master of Science degree in Clinical Research from Case Western Reserve University. He completed a post-doctoral fellowship at Baylor College of Medicine in Houston, Texas followed by neurology residency, and neuroimmunology fellowship at The Cleveland Clinic. Dr. Ontaneda was the recipient of a highly competitive Sylvia Lawry
Dr. Daniel Ontaneda is an Assistant Professor of Medicine/Neurology at The Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and Staff Neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic. He received his medical degree from The Pontificia Universidad CatoÃŒÂlica del Ecuador and holds a Master of Science degree in Clinical Research from Case Western Reserve University. He completed a post-doctoral fellowship at Baylor College of Medicine in Houston, Texas followed by neurology residency, and neuroimmunology fellowship at The Cleveland Clinic. Dr. Ontaneda was the recipient of a highly competitive Sylvia Lawry Research Fellowship Award through the National Multiple Sclerosis Society. He is also the recipient of a National Institutes of Health KL2 award and his research is focused on advanced MRI imaging outcomes for clinical trials in progressive forms of MS.
After completing his postdoctoral training at Baylor College of Medicine in 2002, Dr. Xuefeng Xia joined the University of Texas Health Science Center at Houston as an instructor. Dr. Xia was appointed to assistant professor of medicine at the University of Texas Health Science Center in 2006. He was appointed assistant member at the Houston Methodist Research Institute in 2008. Dr. Xias research projects focus on liver and kidney disease function and disease states, and span the Genomic Medicine and Diabetes & Metabolic Disease research programs at the Research Institute. Dr. Xia is also a member of American Gastroenterology Association
After completing his postdoctoral training at Baylor College of Medicine in 2002, Dr. Xuefeng Xia joined the University of Texas Health Science Center at Houston as an instructor. Dr. Xia was appointed to assistant professor of medicine at the University of Texas Health Science Center in 2006. He was appointed assistant member at the Houston Methodist Research Institute in 2008. Dr. Xias research projects focus on liver and kidney disease function and disease states, and span the Genomic Medicine and Diabetes & Metabolic Disease research programs at the Research Institute. Dr. Xia is also a member of American Gastroenterology Association and The Endocrine Society.
Dr. Abhijit Ghatak completed his MBBS from Grant Medical College and Sir J.J Group of Hospitals, University of Mumbai, India. After completing a post-graduation training in United Kingdom he became a Member of Royal College of Physicians (MRCP, London U.K). He is also American board certified in Internal Medicine. He worked as Internal medicine resident at University of Connecticut Health Center CT, USA. He published more than 20 papers and has given multiple poster and oral presentations at various national and international conferences. He is the member of American College of Cardiology, American College of Physicians, Member of Royal College
Dr. Abhijit Ghatak completed his MBBS from Grant Medical College and Sir J.J Group of Hospitals, University of Mumbai, India. After completing a post-graduation training in United Kingdom he became a Member of Royal College of Physicians (MRCP, London U.K). He is also American board certified in Internal Medicine. He worked as Internal medicine resident at University of Connecticut Health Center CT, USA. He published more than 20 papers and has given multiple poster and oral presentations at various national and international conferences. He is the member of American College of Cardiology, American College of Physicians, Member of Royal College of Physicians, London, United Kingdom, General Medical Council, United Kingdom, Medical Council of India, India.
Accomplished Executive PhD professional Leader with extensive experience in Drug Discovery, Development and Global Health Authority Approvals of drugs to treat human diseases ranging from pain, inflammation, emesis associated with cancer therapy, Alzheimers disease, obesity, congestive heart failure, glaucoma, age-related macular degeneration, ocular allergies, uveitis, dry eye, etc. Specific expertise in Biochemical Pharmacology, In Vivo Pharmacology, Biotherapeutics [Biologics] and Imaging Technologies applied in academic and pharmaceutical industry settings. Globally-recognized technical and leadership experience in pharmaceutical industry. Prior academic background at postdoctoral level, teaching and mentoring of university interns and graduate students. Adjunct professor at multiple universities and thesis advisor and
Accomplished Executive PhD professional Leader with extensive experience in Drug Discovery, Development and Global Health Authority Approvals of drugs to treat human diseases ranging from pain, inflammation, emesis associated with cancer therapy, Alzheimers disease, obesity, congestive heart failure, glaucoma, age-related macular degeneration, ocular allergies, uveitis, dry eye, etc. Specific expertise in Biochemical Pharmacology, In Vivo Pharmacology, Biotherapeutics [Biologics] and Imaging Technologies applied in academic and pharmaceutical industry settings. Globally-recognized technical and leadership experience in pharmaceutical industry. Prior academic background at postdoctoral level, teaching and mentoring of university interns and graduate students. Adjunct professor at multiple universities and thesis advisor and supervisor for MS and PhD students. Organizer, chairman and invited speaker at numerous global symposia and workshops. On editorial boards of several journals. Solid track record of building and maintaining R&D infrastructure and processes, talent acquisition and retention. Technical assessment of in-licensing opportunities. Ability to multi-task. Enjoys a blend of science, medicine, and business in interactions with scientific partners, regulatory and medical affairs, sales and marketing, and KOLs in development of new therapeutic agents. Management of CRO collaborative studies. Focused on driving scientific excellence throughout the organization resulting in strong business impact. Experienced in pharmaceutical Regulatory Affairs [responsible for US FDA approval of Simbrinza and IZBA]. Excellent interpersonal, organizational, planning and task prioritization skills. First awardee of the Dr. Vogel Award for Pharmaceutical Research (2014). Elected as Fellow of ARVO (FARVO) and awarded Silver Medal (Jan.2015).
Dr. Hoa Van Le, MD, PhD is a physician and scientist. He obtained his MD from Odessa National Medical University, completed his Internal Medicine training and practiced as a physician for several years. He pursued his PhD in Pharmacoepidemiology and Biostatistics at the University of North Carolina at Chapel Hill. He won several prestigious awards, such as the SafetyWorks Innovation Award, for developing the semi-automated active drug surveillance application. This won the Best Practices Award of the Bio-IT World (2009). He has been a peer-reviewer for several journals: Annals of Internal Medicine, American Journal of Epidemiology, Pharmacoepidemiology and Drug
Dr. Hoa Van Le, MD, PhD is a physician and scientist. He obtained his MD from Odessa National Medical University, completed his Internal Medicine training and practiced as a physician for several years. He pursued his PhD in Pharmacoepidemiology and Biostatistics at the University of North Carolina at Chapel Hill. He won several prestigious awards, such as the SafetyWorks Innovation Award, for developing the semi-automated active drug surveillance application. This won the Best Practices Award of the Bio-IT World (2009). He has been a peer-reviewer for several journals: Annals of Internal Medicine, American Journal of Epidemiology, Pharmacoepidemiology and Drug Safety, etc. He was named the Best Reviewer of 2012 by the Annals of Internal Medicine. He serves as an Editor for 2 other journals, the Chair of Scientific Committee and a Judge for best poster awards in scientific conferences. His research interests include innovative methods for drug safety and risk management. As the first author, he has published papers on innovative drug safety methodology, a book Atopic Dermatitis, and presented many studies at international conferences.
Dr. Taheri is a house staff in Department of Internal Medicine at Wake Forest School of Medicine. He completed his medical school, internship, and dermatology residency at Tehran University of Medical Science. He joined the Center for Dermatology Research at Wake Forest University as a researcher at 2012. Dr. Taheri serves on the editorial board of Journal of Dermatological Treatment and journal of Experimental Dermatology and Clinical Research. His chief clinical and research interests are psoriasis, eczema, autoimmune diseases and the dermatologic manifestations of systemic diseases, wound healing and scar prevention, as well as electrosurgery. He is a researcher and
Dr. Taheri is a house staff in Department of Internal Medicine at Wake Forest School of Medicine. He completed his medical school, internship, and dermatology residency at Tehran University of Medical Science. He joined the Center for Dermatology Research at Wake Forest University as a researcher at 2012. Dr. Taheri serves on the editorial board of Journal of Dermatological Treatment and journal of Experimental Dermatology and Clinical Research. His chief clinical and research interests are psoriasis, eczema, autoimmune diseases and the dermatologic manifestations of systemic diseases, wound healing and scar prevention, as well as electrosurgery. He is a researcher and expert in the field of effects of high frequency electrical currents on biological tissues.
Dale Ding obtained his M.D. from Duke University and is currently a senior neurosurgery resident at the University of Virginia. He has published over 100 articles, primarily in the field of cerebrovascular disease and in top subspecialty journals, such as the Journal of Neurosurgery, Neurosurgery, American Journal of Neuroradiology, Cerebrovascular Diseases, and Journal of Cerebral Blood Flow and Metabolism, and has presented over 40 abstracts at national and regional meetings. He serves as the Associate Editor of Neuroimmunology and Neuroinflammation and presides on the editorial boards of JSciMed Neurosurgery and Spine, Journal of Cerebrovascular Disease, Austin Journal of Cerebrovascular Disease
Dale Ding obtained his M.D. from Duke University and is currently a senior neurosurgery resident at the University of Virginia. He has published over 100 articles, primarily in the field of cerebrovascular disease and in top subspecialty journals, such as the Journal of Neurosurgery, Neurosurgery, American Journal of Neuroradiology, Cerebrovascular Diseases, and Journal of Cerebral Blood Flow and Metabolism, and has presented over 40 abstracts at national and regional meetings. He serves as the Associate Editor of Neuroimmunology and Neuroinflammation and presides on the editorial boards of JSciMed Neurosurgery and Spine, Journal of Cerebrovascular Disease, Austin Journal of Cerebrovascular Disease & Stroke, and Austin Journal of Radiation Oncology & Cancer. Additionally, he serves as an ad hoc reviewer for over 20 journals, including Neurology, Experimental Biology and Medicine, and British Journal of Neurosurgery.His research interests are Radiosurgery outcomes for cerebral arteriovenous malformations and skull base meningiomas, pathogenesis of intracranial aneurysms, role of inflammation in cerebrovascular disease, endovascular treatment of intracranial aneurysms and vascular malformations, surgical treatment of intracranial aneurysms and vascular malformations.
Dr. John Rothman studied at the Department of Pharmacology at the Tulane University School of Medicine in the laboratory of Dr. Louis Ignarro (Nobel Prize; Medicine, 1998) and conducted his graduate research in the laboratory of Dr. Andrew Schally (Nobel Prize; Medicine, 1977). He oversaw the first trial in AIDS while at Schering Plough. At and Hoffmann LaRoche, where he was also a Clinical Director for GI, CNS, ID and other areas, and Senior Director for all of Roches data acquisition, statistical analysis and report writing for all experimental and approved drugs. His work in Kaposis sarcoma with Genentechs
Dr. John Rothman studied at the Department of Pharmacology at the Tulane University School of Medicine in the laboratory of Dr. Louis Ignarro (Nobel Prize; Medicine, 1998) and conducted his graduate research in the laboratory of Dr. Andrew Schally (Nobel Prize; Medicine, 1977). He oversaw the first trial in AIDS while at Schering Plough. At and Hoffmann LaRoche, where he was also a Clinical Director for GI, CNS, ID and other areas, and Senior Director for all of Roches data acquisition, statistical analysis and report writing for all experimental and approved drugs. His work in Kaposis sarcoma with Genentechs IFN-alpha, became the basis for the first Biologics License Application which was the first approved recombinant drug and AIDS therapeutic agent. He has been a VP of a medical marketing company, the principal in a Princeton technology fund, the Executive VP of a biotech company, and consultant to a number of Wall Street funds.
Dr. Xie received Ph.D in Physiology in 2004 from Xian Jiaotong University. He received lots of awards, including Excellent Natural Science Thesis of Shaanxi Province and Excellent Thesis of Hsi-Chun Chang Foundation from Chinese Association for Physiological Sciences. After graduation, Dr. Xie pursued postdoctoral training in University of Toronto and University of Florida State University. Then he served as research associate in several north America universities including University of Tennessee, University of Western Ontario, University of Manitoba, University of Toronto. Dr Xie is interested in the fields of pain, synaptic plasticity, neurodegenerative diseases, etc. In the past years, Dr. Xie
Dr. Xie received Ph.D in Physiology in 2004 from Xian Jiaotong University. He received lots of awards, including Excellent Natural Science Thesis of Shaanxi Province and Excellent Thesis of Hsi-Chun Chang Foundation from Chinese Association for Physiological Sciences. After graduation, Dr. Xie pursued postdoctoral training in University of Toronto and University of Florida State University. Then he served as research associate in several north America universities including University of Tennessee, University of Western Ontario, University of Manitoba, University of Toronto. Dr Xie is interested in the fields of pain, synaptic plasticity, neurodegenerative diseases, etc. In the past years, Dr. Xie published over 30 peer-reviewed papers. He serves as peer reviewer for Journal of Pharmacology & Pharmacy, Neurological Science, Acta Pharmacologic Sina, Neuroscience Letters, Neural Regeneration Research. He is also the editorial board member of World Journal of Anesthesiology, Journal of Scientific Research and Studies, Exploratory Research and Hypothesis in Medicine (ERHM) Journal, Exploratory Research and Hypothesis in Pharmacology (ERHP) Journal.
Suhail Rasool work as an Physiology and Neuroscience, School of Medicine for NYU Langone Medical Center at 550 1st Ave New York, USA. He has 2-3 years of experience in teaching and supervising undergraduate and graduate medical students. He has done his Postdoctoral Fellow in the Department of Molecular Biology and Biochemistry UC Irvine, USA. He is Senior Research Fellow at the All India Institute of Medical Sciences New Delhi India.
Suhail Rasool work as an Physiology and Neuroscience, School of Medicine for NYU Langone Medical Center at 550 1st Ave New York, USA. He has 2-3 years of experience in teaching and supervising undergraduate and graduate medical students. He has done his Postdoctoral Fellow in the Department of Molecular Biology and Biochemistry UC Irvine, USA. He is Senior Research Fellow at the All India Institute of Medical Sciences New Delhi India.
Dr Louboutin, MD, PhD, is a Neurologist interested in gene therapy/cell therapy as well as in neurovirology. He recently focused his work on the role of oxidative stress in the neuropathogenesis of HIV-1. By developing different animal models of HIV-1 Associated Neurocognitive Disorder (HAND), he studied the deleterious effects of HIV-1 envelope glycoprotein gp120 and non-structural protein Tat in the brain. Gene delivery of antioxidant enzymes SOD1 and GPx1 in different situations, and assessed in different experimental settings, protected neurons against gp120-and Tat-induced apoptosis and other harmful effects. Gene delivery to the spinal cord, either intravenously or intrathecally, resulted in
Dr Louboutin, MD, PhD, is a Neurologist interested in gene therapy/cell therapy as well as in neurovirology. He recently focused his work on the role of oxidative stress in the neuropathogenesis of HIV-1. By developing different animal models of HIV-1 Associated Neurocognitive Disorder (HAND), he studied the deleterious effects of HIV-1 envelope glycoprotein gp120 and non-structural protein Tat in the brain. Gene delivery of antioxidant enzymes SOD1 and GPx1 in different situations, and assessed in different experimental settings, protected neurons against gp120-and Tat-induced apoptosis and other harmful effects. Gene delivery to the spinal cord, either intravenously or intrathecally, resulted in long-term transgene expression in neurons of the spinal cord. Another field of interest are the neurological manifestations linked to HTLV-1 and their pathogenesis. Dr Louboutin is currently in Jamaica trying to get a better understanding of the physiopathology of tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). The current collaboration with the Gene Therapy Program of the University of Pennsylvania is focused on gene therapy approach in different neurodegenerative disorders. Finally, Dr Louboutin is involved in cell therapy using stem cells in different tissues. This approach emphasizes the interaction with regenerative medicine in a translational context. Intramarrow gene delivery of SV40-derived vectors downregulating CCR5 resulted in the reduction of excitotoxin-induced seizures and their harmful consequences. These results emphasize the role of CCR5 in the immune-mediated process underlying some forms of epilepsy. He is the author of more than 80 papers in peer-reviewed journals and more than 12 book chapters. His Research interests are HIV-1- HTLV-1-Gene transfer, Cell therapy, Neuroscience, Oxidative stress, Blood- brain barrier, Neurovirology- Neurology.
Dr. Xin Su is a Principal Research Scientist at Medtronic, Inc. Minneapolis, Minnesota. She received a Medical degree in 1985 and MSci. degree in 1990 from Hebei Medical University, China. Dr. Su has broad knowledge in preclinical and early phase clinical research in drug discovery and device development. She has significant research experience in pain and urology with a number of peer-reviewed papers and book chapters.
Dr. Xin Su is a Principal Research Scientist at Medtronic, Inc. Minneapolis, Minnesota. She received a Medical degree in 1985 and MSci. degree in 1990 from Hebei Medical University, China. Dr. Su has broad knowledge in preclinical and early phase clinical research in drug discovery and device development. She has significant research experience in pain and urology with a number of peer-reviewed papers and book chapters.
All articles are fully peer reviewed, free to access and can be downloaded from our ClinMed archive.
Clinical Medical Image Library: 93.51
International Journal of Critical Care and Emergency Medicine: 92.83
International Journal of Sports and Exercise Medicine: 91.84
International Journal of Womens Health and Wellness: 91.79
Journal of Musculoskeletal Disorders and Treatment: 91.73
Journal of Geriatric Medicine and Gerontology: 91.55
Journal of Infectious Diseases and Epidemiology: 91.55
Clinical Medical Reviews and Case Reports: 91.40
International Archives of Nursing and Health Care: 90.87
International Journal of Ophthalmology and Clinical Research: 90.80
International Archives of Urology and Complications: 90.73
Journal of Clinical Nephrology and Renal Care: 90.33
Journal of Family Medicine and Disease Prevention: 89.99
Journal of Clinical Gastroenterology and Treatment: 89.54
Journal of Dermatology Research and Therapy: 89.34
International Journal of Clinical Cardiology: 89.24
International Journal of Radiology and Imaging Technology: 88.88
Obstetrics and Gynaecology Cases - Reviews: 88.42
International Journal of Blood Research and Disorders: 88.22
International Journal of Diabetes and Clinical Research: 87.97